Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584556 | 0.82 | HDAC1 (0.44) | HDAC1HDAC6ALDH1A1 | |
| SCHEMBL30294888 | 0.75 | RAPGEF4 (0.35) | HDAC1HDAC6 | |
| SCHEMBL13349219 | 0.75 | HDAC1 (0.35) | HDAC1HDAC6 | |
| SCHEMBL27871748 | 0.75 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL24136102 | 0.75 | TTR (0.43) | HDAC1HDAC6 | |
| SCHEMBL3458855 | 0.75 | RAPGEF4 (0.35) | HDAC1HDAC6 | |
| SCHEMBL28872076 | 0.75 | CYP3A4 (0.38) | HDAC1HDAC6ALDH1A1 | |
| SCHEMBL5305665 | 0.75 | HDAC1 (0.35) | HDAC1HDAC6 | |
| SCHEMBL20828819 | 0.75 | DGAT1 (0.30) | — | |
| SCHEMBL17695758 | 0.73 | NMT1 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4430037-B1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250122186-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4430037-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118510775-A | Isoxazolidines as RIPK1 inhibitors and their use | 建新公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240109882-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2024-04-04 | — | — | US | disclosed |
| US-11897876-B2 | Isoxazolidines as RIPK1 inhibitors and use thereof | GENZYME CORPORATION (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230203027-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023083847-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203027-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK2, RIPK3 | HDAC1 1446/4885HDAC6 1711/4885ALDH1A1 4315/4885 |
| US-20240109882-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK2, RIPK3 | HDAC1 1446/4885HDAC6 1711/4885ALDH1A1 4315/4885 |
| US-11897876-B2 | Isoxazolidines as RIPK1 inhibitors and use thereof | RIPK1, RIPK2, RIPK3 | HDAC1 1446/4885HDAC6 1711/4885ALDH1A1 4315/4885 |
| US-20250122186-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK2, RIPK3 | HDAC1 1446/4885HDAC6 1711/4885ALDH1A1 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.